Sirenade: Disentangling Alzheimer's

Most companies developing therapies for Alzheimer's disease focus on the development of drugs and vaccines to prevent or to destroy the plaques that typically accumulate in the brains of AD patients. Sirenade Pharmaceuticals AG believes that this strategy must be complemented with a treatment directed at the neurofibrillary tangles also associated with AD. The company claims it has a substance that does the trick.

Scientists have suspected for

Read the full 673 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE